omniture
德琪(浙江)医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD

Latest News

Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer

SHANGHAI and HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-01-05 08:00 3310

Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL

SHANGHAI and HONG KONG, Jan. 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-01-04 08:00 4161

Antengene Announces Collaboration with Applied BioMath, LLC for Systems Pharmacology Modeling in Oncology

SHANGHAI and HONG KONG, Dec. 9, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2020-12-09 08:00 3582

Antengene Announces Acceptance of IND Application in China for ATG-010 (selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

SHANGHAI and HONG KONG, Dec. 7, 2020 /PRNewswire/ --  Antengene Corporation Limited ("Antengene", ...

2020-12-07 08:00 3711

Antengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL

SHANGHAI and HONG KONG, Dec. 3, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2020-12-03 20:00 5911

Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Nov. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK)...

2020-11-20 21:09 13068

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

SHANGHAI, Oct. 10, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative biopharmaceuti...

2020-10-15 08:59 2806

Antengene's New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer

SHANGHAI, Oct. 12, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative biopharmaceutic...

2020-10-12 20:00 5152

Australian Therapeutic Goods Administration Approves the First Phase I Trial of ATG-017 for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies

SHANGHAI and MELBOURNE, Australia, Aug. 13, 2020 /PRNewswire/ -- Antengene Corporation, a leading i...

2020-08-13 06:00 2598

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

SHANGHAI, July 20, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative hematology and ...

2020-07-20 08:00 9476

Antengene Appoints Former Celgene ANZ Medical Leader Dirk Hoenemann as Head of Medical Affairs in Asia Pacific Region & Early Clinical Development

SHANGHAI and MELBOURNE, Australia, July 13, 2020 /PRNewswire/ -- Antengene Corporation (Antengene) ...

2020-07-13 06:00 4716

­Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions

SHANGHAI and PHILADELPHIA, July 1, 2020 /PRNewswire/ --Antengene Corporation today announced its a...

2020-07-02 08:16 1581

Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer

SHANGHAI and HONG KONG, June 8, 2020 /PRNewswire/ -- Antengene Corporation (Antengene) today announ...

2020-06-08 20:00 2272

Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets

SHANGHAI, May 5, 2020 /PRNewswire/ -- Antengene Corporation (Antengene) today announced a broaden...

2020-05-05 20:30 2031

Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin's Lymphoma

SHANGHAI and PHILADELPHIA, April 14, 2020 /PRNewswire/ -- Antengene announced today that it has dos...

2020-04-14 21:15 1510
1 ... 56789